SOURCES SOUGHT
66 -- ACEA Biosciences xCELLigence RTCA (Real-time Cell Analyzer)-DP.
- Notice Date
- 7/31/2015
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-HG-2015-165-KEW-SBSS
- Archive Date
- 8/29/2015
- Point of Contact
- Kyle Wisor, Phone: 3014023670, Rashida Ferebee,
- E-Mail Address
-
Kyle.Wisor@nih.gov, rashida.ferebee@nih.gov
(Kyle.Wisor@nih.gov, rashida.ferebee@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- A. Small Business Sources Sought Notice: NHLBI-CSB-HG-2015-165-KEW-SBSS B. Title: ACEA Biosciences xCELLigence RTCA (Real-time Cell Analyzer)-DP. C. This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources; and (2) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method. All capability Statements sent in response to this SMALL BUISNESS SOURCES SOUGHT notice must be submitted electronically (via email) to Kyle Wisor, Contract Specialist, at kyle.wisor@nih.gov in either MS Word or Adobe Portable Document Format (PDF), by August 14th, 2015 9:00 AM, EASTERN TIME under Solicitation Number: NHLBI-CSB-HG-2015-165-KEW-SBSS. FAXES ARE NOT ACCEPTED D. Information: 1. Background The National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), Oral Pharyngeal Cancer Branch (OPCB) is researching therapies for tumor treatments. A tumor vaccine is the one of the most promising therapies for tumor treatment among multiple methods of immunotherapy. The vaccine would activate the tumor-specific immunity without affecting the normal tissues. However, the tumor immunity induced by the tumor vaccine may undergo a process called tumor editing in the tumor microenvironment, where the tumor cells may escape the effects of the vaccine, resulting in low immunogenicity, especially in solid tumors. The regulatory T cell (Treg, a type of white blood cell) is one of the important mechanisms by which tumor editing occurs, and these cells can suppress the immune system by directly contacting tumor-specific cytotoxic T cells or through producing proteins called cytokines. Therefore, inhibiting the functions of Treg cells during tumor vaccine treatment may be the solution to increasing the efficiency of tumor-specific immunity. 2. Purpose and Objectives This project is aim to induce high efficiency immunotherapy by combining tumor antigen vaccine and inhibition of regulatory T cells (Treg). In order to figure out the mechanism of the roles of effector and regulatory T cells during anti-tumor immunity, in vitro assay about the tumor-specific T cells will be performed about cell proliferation and cytotoxic efficiency. It would be helpful to have the ACEA RCTA-DP to help the labs tumor assays and other adherent cell experiments. 3. Project Requirements i. The contractor shall provide the ACEA Biosciences xCELLigence RTCA (Real-time Cell Analyzer)-DP, product number 00380601050. Quantity: 1 ii. Specifications a. RTCA DP Plate Station and Analyzer 1. Electrical input: +6V DC, 5 W max 2. Electronic switch resistance: 2-5 ohm 3. Electrical interface: handling three E-Plate® 16 devices or 3 IM-Plate devices 4. Communications: RS232 serial communications at a band rate of 57600 bits/second 5. Environment: 15° C to 40° C, relative humidity: 98% max non-condensing 6. Output test signal: 22mV rms ± (2% +5 mVrms) @ 10, 25 and 50 kHz 7. Impedance measure accuracy: ± (2% + 1.5 ohm) 8. Impedance measurement repeatability: 0.5% 9. Impedance dynamic range: 5 ohm to 2 kohm 10. Environment: 5° C to 40° C, Relative humidity: 80% max. up to 31° C decreasing linearly to 50% max at 40° C b. RTCA DP Software 1. User friendly GUI (Graphical User Interface) 2. Flexible experimental protocol setup 3. Real-time data acquisition 4. Real-time numeric and graphic data display 5. Multiple output formats c. RTCA DP WorkStation 1. Laptop computer capable of running RTCA DP Software 4. Anticipated Period of Performance/Delivery Date Delivery Date: To Be Decided 5. Capability Statement Interested parties are expected to review this notice to familiarize itself with the requirements of this project. Failure to do so will be at your firm's own risk. The following information shall be included in the capability statement: a. A general overview of the respondents' opinions about the difficulty and /or feasibility of the potential requirement, and any information regarding innovative ideas or concepts. b. Information as needed in sufficient details of the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts, references, and other related information. c. The respondents' DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZONE, etc) pursuant to the North American Industry Classification System (NAICS) code: 334516, Analytical Laboratory Instrument Manufacturing, Small Business Size 500 employees. d. Any other information that may be helpful in developing or finalizing the requirements of the potential acquisition. e. The capability statement shall not exceed 20 single-sided pages (including all attachments, resumes, charts, etc.) presented in single-space and using a 12-point font size minimum, in either Microsoft Word or Adobe Portable Document Format (PDF), with 8-1/2 by 11 inch paper size, and 1 inch top, bottom, left and right margins. f. All proprietary information should be marked as such. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferably placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 6. Closing Statement All capability Statements sent in response to this SMALL BUISINESS SOURCES SOUGHT notice must be submitted electronically (via email) to Kyle Wisor, Contract Specialist, at kyle.wisor@nih.gov in either MS Word or Adobe Portable Document Format (PDF), by August 14th, 2015 9:00 AM, EASTERN TIME under Solicitation Number: NHLBI-CSB-HG-2015-165-KEW-SBSS. FAXES ARE NOT ACCEPTED. This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this notice, the NHLBI may issue a Request for Quote (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NHLBI shall arise as a result of a response to this notice or the NHLBI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. "Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-HG-2015-165-KEW-SBSS/listing.html)
- Place of Performance
- Address: National Institutes of Health, NIDCR, 30 Convent Drive, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03819872-W 20150802/150731235629-4e3ef7619c3ed45d3bd287471e2db457 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |